TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Tonix Pharma ( (TNXP) ) is now available.
On November 17, 2025, Tonix Pharmaceuticals announced that its product, TONMYATM (cyclobenzaprine HCl sublingual tablets), is now commercially available by prescription in U.S. pharmacies. This development marks a significant step for the company, potentially enhancing its market presence and offering new treatment options for patients, thereby impacting stakeholders positively.
The most recent analyst rating on (TNXP) stock is a Sell with a $17.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Underperform.
Tonix Pharma’s overall stock score is primarily impacted by its financial performance and valuation challenges. The company faces significant profitability and cash flow issues, which are reflected in its negative P/E ratio. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and approaching oversold conditions. These factors collectively contribute to a low overall stock score.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development and commercialization of pharmaceutical products. The company is known for its innovative solutions in drug development, particularly in the areas of central nervous system disorders and immunology.
Average Trading Volume: 1,108,940
Technical Sentiment Signal: Sell
Current Market Cap: $187.2M
For detailed information about TNXP stock, go to TipRanks’ Stock Analysis page.